Search Results
Your search for ,maY matches 17180 pages
Showing 1801 - 1850Novel CAR T-Cell Therapy May Show Benefit in Patients With Advanced Clear Cell Renal Cell Carcinoma
The CD70-targeted allogeneic chimeric antigen receptor (CAR) T-cell therapy CTX130 may be effective in patients with advanced clear cell renal cell carcinoma, according to findings presented by Srour et al at the American Association for Cancer Research (AACR) Annual Meeting 2024 (Abstract CT002)...
Can a Personalized Antitumor Vaccine Plus Pembrolizumab Improve Outcomes in Hepatocellular Carcinoma?
Adding a personalized antitumor vaccine to the PD-1 inhibitor pembrolizumab may be safe and about twice as effective at shrinking tumors in patients with hepatocellular carcinoma compared with pembrolizumab alone, according to new findings presented by Yarchoan et al at the American Association for ...
FDA Grants Accelerated Approval to Fam-Trastuzumab Deruxtecan-nxki for Unresectable or Metastatic HER2-Positive Solid Tumors
On April 5, the U.S. Food and Drug Administration (FDA) granted accelerated approval to fam-trastuzumab deruxtecan-nxki (Enhertu) for adult patients with unresectable or metastatic HER2-positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior systemic treatment and have no...
Accelerated Aging May Be a Risk Factor for Early-Onset Cancers in Younger Generations
According to recent studies, the incidence of early-onset cancers—often defined as those diagnosed in individuals younger than age 50—is on the rise, and not just in the United States but globally as well. Research shows that between 1990 and 2019, the global incidence of early-onset cancer...
Fewer Than Half of Drugs Granted Accelerated Approval Demonstrated Benefit Within 5 Years
In 1992, the U.S. Food and Drug Administration (FDA) instituted its Accelerated Approval regulations, which allow drugs that treat serious conditions and fill an unmet need to be approved early based on a surrogate endpoint. However, any drug approved under this pathway is still required to undergo ...
Judy C. Boughey, MD, on De-escalating Axillary Surgery After Chemotherapy for Breast Cancer
Judy C. Boughey, MD, of the Mayo Clinic, discusses findings from the I-SPY2 trial, which show that although the extent of residual disease and tumor biology in patients with breast cancer may impact outcomes, the type of axillary surgery after neoadjuvant chemotherapy does not (Abstract 3).
Improving Adjuvant Treatment in Patients With Muscle-Invasive Urothelial Carcinoma
Two recent studies have offered new insights into the treatment of muscle-invasive urothelial carcinoma following cystectomy, according to findings presented by Powles et al and Galsky et al at the European Association of Urology Congress 2024. The research could allow physicians to target...
Distinct Microbial Signature Uncovered in KRAS-Mutated Colorectal Cancer
Researchers have identified microbiota signatures that are associated with KRAS mutations in patients with colorectal cancer, according to a recent study published by Huang et al in Microbiology Spectrum. The findings suggest that gut microbes may serve as a noninvasive biomarker for subtypes of...
Rwanda’s Progress in Eradicating Hepatitis C Virus: A Feasible Approach to Reducing Liver Cancer Incidence in Sub-Saharan Africa
Of 58 million people worldwide living with hepatitis C virus (HCV), one-sixth of them are found in sub-Saharan Africa.1 Yet, in that region, direct access to diagnostic testing and treatment is limited to less than 5%. HCV carries significant downstream implications including cirrhosis (30%–46%), ...
Feasibility of Ending Specialist Follow-up in Patients With Low-Risk CLL
A study published by Brieghel et al in Blood Advances showed that among patients in Denmark who had slow-growing chronic lymphocytic leukemia (CLL) with no symptoms and a low risk for ever needing treatment, those who stopped seeing their doctors for specialized follow-up had fewer hospital visits, ...
Can Artificial Intelligence Predict Treatment Response and Outcomes in Breast Cancer?
Artificial intelligence (AI)—computational analytics with routine imaging via radiology or pathology—can advance precision medicine in breast cancer, specifically by predicting response to therapy and calculating prognosis, according to a pioneer in the field, Anant Madabhushi, PhD, of Emory...
Study Examines Shared Decision-Making Policies and Practices Around Lung Cancer Screening
A Medicare policy requiring shared decision-making between primary care physicians and patients regarding whether to proceed with lung cancer screening may require further examination, according to a recent study published by Kale et al in the Annals of Family Medicine. The findings indicated that...
Asking ChatGPT About Radiation Oncology Treatment
Researchers examined whether the artificial intelligence (AI)-based chatbot ChatGPT can help provide answers to patients with cancer regarding radiation oncology treatment, according to a recent study published by Yalamanchili et al in JAMA Network Open. Background Over 60% (n = 500,000) of...
Can TILs Help to Determine Outcomes in Triple-Negative Breast Cancer?
High levels of tumor-infiltrating lymphocytes (TILs) within the tumors of patients with early-stage triple-negative breast cancer may be associated with a lower risk of cancer recurrence and greater rate of survival, even without chemotherapy, according to a recent study published by Leon-Ferre et...
Microwave Ablation vs Surgical Resection in Multifocal Papillary Thyroid Carcinoma
Microwave ablation may offer comparable progression-free survival rates and fewer complications in patients with papillary thyroid carcinoma compared with surgical resection, according to a recent study published by Zhao et al in Radiology. Background Papillary thyroid carcinoma—the most common...
Model for Predicting Outcomes After Sentinel Lymph Node Biopsy in Melanoma
In a study reported in The Lancet Oncology, Stassen et al developed a model for the prediction of recurrence-free and melanoma-specific survival after sentinel lymph node biopsy (SLNB) in patients with melanoma. Study Details The study involved a development cohort of 4,071 patients aged > 13...
Benefit of Prostate MRI Plus PSA Density Test in Patients Suspected of Having Prostate Cancer
Investigators have found that combining a prostate magnetic resonance imaging (MRI) scan with a prostate-specific antigen (PSA) density test may help diagnose clinically significant prostate cancer and avoid unnecessary biopsies, according to a recent systematic review and meta-analysis published...
Tuberculosis May Be Linked to Increased Risk of Various Cancer Types
The risk of certain types of cancer may be higher in patients currently or previously diagnosed with tuberculosis, according to new findings to be presented by Kim et al at the upcoming 2024 European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) annual congress. Background...
Natália Polidorio, MD, PhD, on Triple-Negative Breast Cancer: Impact of Race on Treatment Efficacy
Natália Polidorio, MD, PhD, of Memorial Sloan Kettering Cancer Center, discusses findings on the impact of race on pathologic complete response in patients with early-stage triple-negative breast cancer who received neoadjuvant chemoimmunotherapy vs chemotherapy alone. Such targeted research may...
Treating DCIS: To Escalate or De-escalate?
There is much debate about the necessity of treating women with ductal carcinoma in situ (DCIS) with surgery or radiotherapy.1,2 It is disconcerting to many that patients with DCIS are treated in the same way as are women with early-stage invasive breast cancer. Many patients with DCIS have...
Surveyed Oncologists’ Attitudes Toward Ethical Implications of AI in Cancer Care
Researchers surveyed oncologists for their perspectives on how artificial intelligence (AI) may be responsibly integrated into some aspects of cancer care as well as how to protect patients from the hidden biases of AI, according to a recent study published by Hantel et al in JAMA Network Open....
NAPRC-Accredited Hospitals vs Nonaccredited Hospitals: Proctectomy Outcomes
Hospitals accredited by the American College of Surgeons (ACS) National Accreditation Program for Rectal Cancer (NAPRC) may demonstrate lower mortality and complication rates in patients undergoing proctectomy compared with nonaccredited hospitals, according to a recent study published by Harbaugh...
NSCLC: Neoadjuvant Chemoimmunotherapy vs Neoadjuvant Chemotherapy
In a systematic review and meta-analysis reported in JAMA Oncology, Sorin et al found that neoadjuvant chemoimmunotherapy was associated with better outcomes than neoadjuvant chemotherapy in patients with non–small cell lung cancer (NSCLC). Study Details A search of published studies reported...
Prolonged Use of Progestogens May Be Linked to Increased Risk of Brain Cancer
Prolonged use of selected progestogen agents may be associated with an increased risk of developing intracranial meningioma, according to a recent study published by Roland et al in the BMJ. Background Progestogens are similar to the natural hormone progesterone, which are widely used in menopausal ...
Malpractice Risk With Active Surveillance for Patients With Low-Risk Cancer
Investigators have assessed medical malpractice trends related to active surveillance as a treatment strategy across different types of cancers, according to a recent study published by Chang et al in the Annals of Surgery. Background Active surveillance is a less invasive approach that reserves...
Inotuzumab Ozogamicin for Relapsed or Refractory Pediatric Acute Lymphoblastic Leukemia
On March 6, 2024, inotuzumab ozogamicin (Besponsa) was approved for pediatric patients aged 1 year or older with relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia.1 Supporting Efficacy Data Approval was based on findings in the ITCC-059 trial (ClinicalTrials.gov...
Amivantamab-vmjw in NSCLC With EGFR Exon 20 Insertion Mutations
On March 1, 2024, amivantamab-vmjw (Rybrevant) was approved for use with carboplatin and pemetrexed for first-line treatment of locally advanced or metastatic non–small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations, as detected by a U.S. Food and Drug Administration (FDA)-approved...
IKZF1 Genetic Variant May Contribute to Disparities in Risk of ALL in Pediatric Hispanic and Latino Patients
A genetic variant located on the IKZF1 gene may be responsible for disparities in the risk of acute lymphoblastic leukemia (ALL) among Hispanic and Latino children, according to a recent study published by de Smith et al in Cell Genomics. The findings offer insights into the causes of the disease...
Novel Drug Combination in Multiple Myeloma
Researchers have found that venetoclax in combination with azacitidine may be effective at treating patients with multiple myeloma, according to a recent study published by Flanagan et al in Haematologica. Background Despite recent advances in the treatment of multiple myeloma, the disease remains ...
Gut Microbiome Signatures May Help Unravel Disparities in Early-Onset Colorectal Cancer
The composition of the gut microbiome may reveal distinct signatures associated with race, ethnicity, and age of onset in patients with colorectal cancer, according to a recent study published by Hein et al in the Journal of Immunotherapy and Precision Oncology. The findings provide insights into...
Subtype of Fusobacterium nucleatum May Be Linked to Colorectal Cancer Progression and Poor Outcomes
Researchers have found that a specific subtype of Fusobacterium nucleatum may be capable of growing within colorectal cancer, driving cancer progression, and leading to poorer outcomes following colorectal cancer treatment, according to a recent study published by Zepeda-Rivera et al in Nature. The ...
Low-Dose Radiotherapy Boost in Young Patients With Breast Cancer
Researchers have found that a low-dose radiotherapy boost in addition to whole-breast radiotherapy may prevent local recurrence in young patients with breast cancer, according to new findings presented by Bosma et al at the 2024 European Breast Cancer Conference (EBCC) (Abstract 4LBA) and...
Response to Primary Systemic Therapy Could Dictate Whether Extensive Lymph Node Removal Is Needed in Patients With Breast Cancer
Extensive removal of the lymph nodes may be safely avoided in patients with breast cancer that has metastasized to the axillary nodes if treatment is tailored to their response to therapies such as chemotherapy prior to surgery, according to new findings presented by van Hemert et al at the 2024...
Integrative Approaches to Managing Symptoms of Anxiety and Depression in Adults With Cancer
Guest Editor’s Note: Psychological distress is highly prevalent in cancer populations throughout the disease trajectory. Integrative modalities are being increasingly used for managing the associated symptoms. In this article, Joke Bradt, PhD, MT-BC, summarizes the latest joint guideline published ...
Promoting Cardiovascular Health in Adult Survivors of Childhood Cancers
Although more than 85% of childhood cancer survivors will achieve a 5-year survival,1 that does not tell the whole tale for these individuals who move into adulthood. They are at excess risk of late mortality, even 40 years out from a cancer diagnosis, from non–cancer-related causes,1 and related...
From Fatal to Fearless: How Patients Can Take Control of Their Disease and Fear Cancer Less
In 1996, at the age of 37, Kathy Giusti was diagnosed with the incurable blood cancer multiple myeloma and told she had about 3 years to live. In the mid-1990s, effective therapies for this second most common blood cancer were nearly nonexistent. Standard of care for myeloma consisted of oral...
Mary McCormack, PhD, MBBS, on Locally Advanced Cervical Cancer: Results From the INTERLACE Trial
Mary McCormack, PhD, MBBS, of University College London Hospitals, NHS Foundation Trust, discusses the global health issue of cervical cancer and a way forward. Phase III findings from the GCIG INTERLACE trial showed that induction chemotherapy with weekly paclitaxel and carboplatin before...
Addition of Atezolizumab to Adjuvant Chemotherapy in Triple-Negative Breast Cancer
The addition of atezolizumab to postsurgery chemotherapy may not benefit patients with triple-negative breast cancer, according to findings recently presented by McArthur et al at the 2024 European Breast Cancer Conference (EBCC; Abstract 1LBA). Background Triple-negative breast cancer is often...
Effect of Exercise on Symptom Burden and Quality of Life in Patients With Metastatic Breast Cancer
Taking part in an exercise program may improve pain, fatigue, and quality of life in patients with metastatic breast cancer, according to recent findings presented by Hiensch et al at the 2024 European Breast Cancer Conference (EBCC; Abstract 1). Background “Although there’s been quite a lot of...
Incidence of Secondary T-Cell Malignancies Following CAR T-Cell Therapy
Investigators have found that second primary malignancies following chimeric antigen receptor (CAR) T-cell therapy were reported in 4.3% of CAR T-cell therapy adverse event reports submitted to the U.S. Food and Drug Administration’s (FDA) Adverse Event Reporting System, with T-cell malignancies...
Updated Immune Classifier May Accurately Identify Patients With Triple-Negative Breast Cancer Who Are Unlikely to Respond to Immunotherapy
A novel genetic test may predict how patients with triple-negative early-stage breast cancer will respond to immunotherapy, according to new findings presented by Wolf et al at the 2024 European Breast Cancer Conference (EBCC) (Abstract 2LBA). The research may help patients who are unlikely to...
Pembrolizumab May Improve Breast Cancer Outcomes Regardless of Age or Menopausal Status
The addition of the immunotherapy drug pembrolizumab to chemotherapy prior to and following surgery may lead to improved outcomes in patients with breast cancer regardless of their age or menopausal status, according to new findings presented by Cardoso et al at the 2024 European Breast Cancer...
Fruquintinib Plus Paclitaxel Under Study as Second-Line Treatment of Gastroesophageal Cancer
The combination of the small molecule inhibitor of VEGFR fruquintinib and the chemotherapy paclitaxel presents a potential new second-line treatment of patients with advanced gastric or gastroesophageal junction adenocarcinoma, according to data presented during the ASCO Plenary Series: February...
ASCO Releases Resource-Stratified Guideline for the Treatment of Metastatic Breast Cancer
ASCO has released a new guideline on the treatment of patients with metastatic breast cancer in resource-constrained settings, where maximal setting–recommended treatments are not available.1 The guideline, designed for clinicians, policymakers, and patients, provides stratified recommendations...
Brachytherapy Boost May Decrease the Duration of Androgen-Deprivation Therapy for High-Risk Prostate Cancer
The optimal management of high-risk prostate cancer remains a topic of ongoing investigation. The quest for therapy that maximizes cancer control while minimizing toxicity is constant. Over the past decade, there has been mounting evidence that the addition of a brachytherapy boost to external-beam ...
CAR T-Cell Therapy Complications: Comparison of Three Testing Modalities
Magnetic resonance imaging (MRI) and lumbar puncture may not always be necessary for diagnosing and managing a serious neurologic complication associated with chimeric antigen receptor (CAR) T-cell therapy, according to a new study published by Mauget et al in Blood Advances. Findings further...
Effect of HER2 Gene–Expression Levels on Outcomes in Metastatic Colorectal Cancer
As reported in the Journal of Clinical Oncology by Battaglin et al, an analysis from the phase III CALGB/SWOG 80405 trial of first-line chemotherapy plus bevacizumab or cetuximab in patients with metastatic colorectal cancer showed differences in outcomes according to HER2 gene–expression status....
Adjuvant Pembrolizumab: A New Option for High-Risk Muscle-Invasive Urothelial Cancer
Adjuvant use of the PD-1 inhibitor pembrolizumab achieved a statistically significant and clinically meaningful improvement in disease-free survival in patients with high-risk muscle-invasive urothelial carcinoma vs observation after surgical resection, according to an interim analysis of the phase ...
Strategies for Cardiovascular Risk Mitigation and Monitoring in Patients With CLL
With a 5-year overall survival of close to 90% in chronic lymphocytic leukemia (CLL), there have been large treatment shifts over the past decade in this disease, which now includes “more disciplines than it did before,” commented medical oncologist Danielle Shafer, DO, of Inova Schar Cancer...
Cabozantinib Plus Atezolizumab Improves Progression-Free Survival
The combination of the tyrosine kinase inhibitor cabozantinib (multiple targets, including MET, AXL, VEGFR2, RET, and FLT ) plus the monoclonal antibody atezolizumab achieved statistically significant improvement in progression-free survival compared with second-line novel hormonal therapy in...
